NO973197L - Kombinert terapeutisk behandling av hyperproliferative sykdommer - Google Patents

Kombinert terapeutisk behandling av hyperproliferative sykdommer

Info

Publication number
NO973197L
NO973197L NO973197A NO973197A NO973197L NO 973197 L NO973197 L NO 973197L NO 973197 A NO973197 A NO 973197A NO 973197 A NO973197 A NO 973197A NO 973197 L NO973197 L NO 973197L
Authority
NO
Norway
Prior art keywords
hyperproliferative diseases
therapeutic treatment
combined therapeutic
period
separate
Prior art date
Application number
NO973197A
Other languages
English (en)
Other versions
NO325418B1 (no
NO973197D0 (no
Inventor
Bruno Tocque
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of NO973197D0 publication Critical patent/NO973197D0/no
Publication of NO973197L publication Critical patent/NO973197L/no
Publication of NO325418B1 publication Critical patent/NO325418B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO19973197A 1995-01-17 1997-07-09 Kombinasjon av et taxoid og en nukleinsyre som koder for p53 for bruk som et medikament samt anvendelser av nevnte kombinasjon. NO325418B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9500436A FR2729295A1 (fr) 1995-01-17 1995-01-17 Traitement therapeutique combine des pathologies hyperproliferatives
PCT/FR1996/000056 WO1996022101A1 (fr) 1995-01-17 1996-01-12 Traitement therapeutique combine des pathologies hyperproliferatives

Publications (3)

Publication Number Publication Date
NO973197D0 NO973197D0 (no) 1997-07-09
NO973197L true NO973197L (no) 1997-07-09
NO325418B1 NO325418B1 (no) 2008-04-21

Family

ID=9475169

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19973197A NO325418B1 (no) 1995-01-17 1997-07-09 Kombinasjon av et taxoid og en nukleinsyre som koder for p53 for bruk som et medikament samt anvendelser av nevnte kombinasjon.

Country Status (21)

Country Link
US (3) US6262032B1 (no)
EP (1) EP0800399B1 (no)
JP (3) JP4580469B2 (no)
KR (1) KR100385266B1 (no)
AT (1) ATE222109T1 (no)
AU (1) AU716364B2 (no)
BR (1) BR9606969A (no)
CA (1) CA2209771C (no)
CZ (1) CZ298710B6 (no)
DE (1) DE69622989T2 (no)
DK (1) DK0800399T3 (no)
ES (1) ES2180729T3 (no)
FI (1) FI119911B (no)
FR (1) FR2729295A1 (no)
HU (1) HU229484B1 (no)
MX (1) MX9704490A (no)
NO (1) NO325418B1 (no)
PT (1) PT800399E (no)
SI (1) SI0800399T1 (no)
SK (1) SK283989B6 (no)
WO (1) WO1996022101A1 (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044396A1 (en) * 1998-04-21 2003-03-06 Elia James P. Methods for treating diseases and increasing longevity
FR2729295A1 (fr) * 1995-01-17 1996-07-19 Rhone Poulenc Rorer Sa Traitement therapeutique combine des pathologies hyperproliferatives
US7087582B1 (en) 1995-09-26 2006-08-08 Regents Of The University Of Michigan Combination for site-specifically transforming cells in vivo comprising a double-balloon catheter and nucleic acid comprising a gene encoding P21
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US20030060434A1 (en) * 1997-02-18 2003-03-27 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
US20030064949A1 (en) * 1998-02-17 2003-04-03 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
AU2002236765A1 (en) 2001-01-16 2002-07-30 Glaxo Group Limited Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
CN1816564B (zh) * 2003-06-30 2010-11-24 洛桑大学 能选择性杀伤癌细胞的RasGAP衍生肽
JPWO2005061007A1 (ja) * 2003-12-24 2007-07-12 学校法人 聖マリアンナ医科大学 癌の抑制方法
WO2005061001A1 (ja) * 2003-12-24 2005-07-07 Locomogene, Inc. 癌の抑制方法
GB0406415D0 (en) * 2004-03-22 2004-04-21 Inst Of Cancer Res The Materials and methods for treatment of cancer
US8124598B2 (en) * 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
US20100111874A1 (en) * 2007-03-19 2010-05-06 University Of Medicine And Dentistry Of New Jresey Method of cancer detection and treatment
US20100160274A1 (en) * 2007-09-07 2010-06-24 Sharon Sageman 7-KETO DHEA for Psychiatric Use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2634833B2 (ja) * 1986-03-28 1997-07-30 ボード オブ トラステイーズ オブ ユニヴアーシテイ オブ イリノイ ヒト細胞における複数薬剤耐性に関連するｄｎａ配列を含むクローンの組成および方法
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
CA2136091A1 (en) * 1992-05-20 1993-11-25 Daniel S. Martin Chemotherapeutic drug combinations
DE69329336D1 (de) * 1992-05-28 2000-10-05 Xenova Ltd Acridin carboxamide zur behandlung von krebs
FR2694296B1 (fr) * 1992-07-30 1994-09-02 Rhone Poulenc Rorer Sa Peptides inhibant l'activité des protéines ras, préparation et utilisation.
US6348352B1 (en) * 1992-09-18 2002-02-19 Canji, Inc. Methods for selectively transducing pathologic mammalian cells using a tumor suppressor gene
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
TW442569B (en) 1993-10-25 2001-06-23 Canji Inc Recombinant adenoviral vector
FR2729295A1 (fr) * 1995-01-17 1996-07-19 Rhone Poulenc Rorer Sa Traitement therapeutique combine des pathologies hyperproliferatives
US5789244A (en) 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US6054467A (en) 1996-07-05 2000-04-25 Sidney Kimmel Cancer Center Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis

Also Published As

Publication number Publication date
ES2180729T3 (es) 2003-02-16
CA2209771C (fr) 2012-01-03
US6262032B1 (en) 2001-07-17
DE69622989T2 (de) 2002-12-05
FR2729295B1 (no) 1997-02-28
JPH10512559A (ja) 1998-12-02
SK283989B6 (sk) 2004-07-07
US7884082B2 (en) 2011-02-08
US20040127437A1 (en) 2004-07-01
AU4542996A (en) 1996-08-07
NO325418B1 (no) 2008-04-21
HUP9802423A2 (hu) 1999-02-01
WO1996022101A1 (fr) 1996-07-25
DK0800399T3 (da) 2002-12-02
NO973197D0 (no) 1997-07-09
KR100385266B1 (ko) 2005-09-07
CZ298710B6 (cs) 2008-01-02
JP4580469B2 (ja) 2010-11-10
CZ226297A3 (en) 1997-10-15
ATE222109T1 (de) 2002-08-15
EP0800399A1 (fr) 1997-10-15
FI973023A (fi) 1997-07-16
JP2012036201A (ja) 2012-02-23
HU229484B1 (en) 2014-01-28
DE69622989D1 (de) 2002-09-19
SI0800399T1 (en) 2002-12-31
BR9606969A (pt) 1997-11-04
SK95797A3 (en) 1997-12-10
FI973023A0 (fi) 1997-07-16
PT800399E (pt) 2002-12-31
FR2729295A1 (fr) 1996-07-19
CA2209771A1 (fr) 1996-07-25
EP0800399B1 (fr) 2002-08-14
KR19980701449A (ko) 1998-05-15
US20010021395A1 (en) 2001-09-13
AU716364B2 (en) 2000-02-24
US20050209177A9 (en) 2005-09-22
JP5031921B2 (ja) 2012-09-26
JP2008133291A (ja) 2008-06-12
HUP9802423A3 (en) 2000-11-28
FI119911B (fi) 2009-05-15
MX9704490A (es) 1997-10-31

Similar Documents

Publication Publication Date Title
NO973197D0 (no) Kombinert terapeutisk behandling av hyperproliferative sykdommer
DE69600596D1 (de) Zweikammer-schrittmacher-anordnung zur kontinuierlichen regelung des av zeitintervalles mit dem ziel, optimierte stimulierung zur behandlung von kardiomyopathien zu erreichen
MX9703621A (es) Nuevos derivados aminoacidos con actividad mejorada para la resistencia a drogas multiples.
PT668763E (pt) Utilizacao de fenserina para a preparacao de medicamentos para tratar doencas do conhecimento
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
IL121272A (en) Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia
IT1290781B1 (it) Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
ZA968905B (en) Transdermal therapeutic system (tts) for administering active substances for drug dependence or drug addiction
DE59608150D1 (de) Transdermales therapeutisches system (tts) zur verabreichung von testosteron
IL118218A0 (en) Terpenoidic derivatives and pharmaceutical compositions containing them
EP0835662A3 (en) A drug for the treatment of cancer
MX9803610A (es) Utilizacion de flupirtina para la profilaxis y la terapia de enfermedades que van a compañadas de un deterioro del sistema celular hermatopoyetico.
IL116733A0 (en) The use of sertraline to treat cancer patients
IT240104Y1 (it) Dispositivo per il trattamento del corpo umano.
ATE295731T1 (de) Olanzapine zur behandlung von drogenmissbrauch
NO953003L (no) Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater
IL156144A0 (en) Novel therapeutic use of a thienylcyclohexylamine derivative
DE29501910U1 (de) Transdermales therapeutisches den Wirkstoff Dimethisoquin enthaltendes System
TR199801887A2 (xx) Bir Na+/H+ - de�i�tiricisi inhibit�r�.
ATE247468T1 (de) Kombinationstherapie von topoisomerase ii toxinen und bis-dioxypiperazinderivaten
CA2197139A1 (en) A drug for the treatment of cancer
NO981020D0 (no) Transdermalt terapautisk system for silatranforbindelser
UA22223A (uk) Спосіб лікуваhhя захворюваhь оргаhа зору
GEP19991781B (en) Means for Treatment of Prostate Diseases
ITBO950090A0 (it) Trattamento estetico di ricondizionamento dei tratti salienti del corpo umano

Legal Events

Date Code Title Description
MK1K Patent expired